For more than 20 years, Cochrane has produced systematic reviews of primary research in human health care and health policy. We are internationally recognized as the highest standard in evidence-based healthcare resources.

The fourth video in the Cochrane Making a Difference series focuses on the Cochrane Review 'Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration', published in September 2014 from the Cochrane Eyes & Vision Group. The review found that the systemic safety of bevacizumab for macular degeneration appears to be similar to that of ranibizumab - an important consideration given that bevacizumab is considerably less expensive than ranibizumab.

Since then this Cochrane Review has had a significant impact. Author Lorenzo Moja, based at the University of Milan, tells the story so far…